Unexpected favorable outcome to etoposide and cisplatin in a small cell lung cancer transformed patient: a case report

Patients with epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer can benefit significantly from EGFR tyrosine-kinase inhibitors (TKIs) treatment, but almost every patient will inevitably develop resistance. The transformation to small cell lung cancer (SCLC) has been described...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Zhanhong, Gu, Yingying, Lin, Xinqing, Ouyang, Ming, Qin, Yinyin, Zhang, Jiexia, Liu, Junjun, Mai, Suiyi, Zhou, Chengzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Bedside-to-Bench Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6741564/
https://www.ncbi.nlm.nih.gov/pubmed/31161851
http://dx.doi.org/10.1080/15384047.2019.1617561

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6741564/
https://www.ncbi.nlm.nih.gov/pubmed/31161851
http://dx.doi.org/10.1080/15384047.2019.1617561

Ejemplares similares